;PMID: 11807663
;source_file_2943.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..42] = [t:0..42]
;1)sentence:[e:48..99] = [t:48..99]
;2)sentence:[e:100..136] = [t:100..136]
;3)section:[e:140..175] = [t:140..175]
;4)section:[e:179..279] = [t:179..279]
;5)sentence:[e:283..432] = [t:283..432]
;6)sentence:[e:433..540] = [t:433..540]
;7)sentence:[e:541..657] = [t:541..657]
;8)sentence:[e:658..776] = [t:658..776]
;9)sentence:[e:777..869] = [t:777..869]
;10)sentence:[e:870..1057] = [t:870..1057]
;11)sentence:[e:1058..1229] = [t:1058..1229]
;12)sentence:[e:1230..1341] = [t:1230..1341]
;13)sentence:[e:1342..1452] = [t:1342..1452]
;14)section:[e:1456..1501] = [t:1456..1501]

;section 0 Span:0..42
;Eur J Pediatr Surg.  2001 Dec;11(6):363-7.
(SEC
  (FRAG (NNP:[0..3] Eur) (NNP:[4..5] J) (NNP:[6..13] Pediatr)
        (NNP:[14..18] Surg) (.:[18..19] .) (CD:[21..25] 2001)
        (IN:[26..32] Dec;11) (-LRB-:[32..33] -LRB-) (CD:[33..34] 6)
        (-RRB-:[34..35] -RRB-) (::[35..36] :) (CD:[36..39] 363)
        (HYPH:[39..40] -) (CD:[40..42] 7.)))

;sentence 1 Span:48..99
;Neuroblastoma: inhibition of progression (Part II).
;[48..61]:malignancy-type:"Neuroblastoma"
(SENT
  (NP-HLN
    (NP (NN:[48..61] Neuroblastoma))
    (::[61..62] :)
    (NP
      (NP (NN:[63..73] inhibition))
      (PP (IN:[74..76] of)
        (NP (NN:[77..88] progression))))
    (PRN (-LRB-:[89..90] -LRB-)
      (NP (NN:[90..94] Part) (CD:[95..97] II))
      (-RRB-:[97..98] -RRB-))
    (.:[98..99] .)))

;sentence 2 Span:100..136
;Basic science in pediatric  surgery.
(SENT
  (NP
    (NP (JJ:[100..105] Basic) (NN:[106..113] science))
    (PP (IN:[114..116] in)
      (NP (JJ:[117..126] pediatric) (NN:[128..135] surgery)))
    (.:[135..136] .)))

;section 3 Span:140..175
;Girgert R, Wittrock J, Schweizer P.
(SEC
  (FRAG (NNP:[140..147] Girgert) (NNP:[148..149] R) (,:[149..150] ,)
        (NNP:[151..159] Wittrock) (NNP:[160..162] J,) (NNP:[163..172] Schweizer)
        (NNP:[173..175] P.)))

;section 4 Span:179..279
;Department of Pediatric Surgery, University of Tubingen, Germany. 
;rainer.girgert@medizin.uni-ulm.de
(SEC
  (FRAG (NNP:[179..189] Department) (IN:[190..192] of)
        (NNP:[193..202] Pediatric) (NNP:[203..210] Surgery) (,:[210..211] ,)
        (NNP:[212..222] University) (IN:[223..225] of) (NNP:[226..234] Tubingen)
        (,:[234..235] ,) (NNP:[236..243] Germany) (.:[243..244] .)
        (``:[246..252] rainer) (NN:[252..268] .girgert@medizin)
        (NN:[268..276] .uni-ulm) (NN:[276..279] .de)))

;sentence 5 Span:283..432
;In neuroblastoma, amplification of the protooncogene N-myc is the most
;important  molecular characteristic predicting a bad outcome for the
;patients.
;[286..299]:malignancy-type:"neuroblastoma"
;[301..314]:variation-type:"amplification"
;[336..341]:gene-rna:"N-myc"
(SENT
  (S
    (PP (IN:[283..285] In)
      (NP (NN:[286..299] neuroblastoma)))
    (,:[299..300] ,)
    (NP-SBJ
      (NP (NN:[301..314] amplification))
      (PP (IN:[315..317] of)
        (NP
          (NP (DT:[318..321] the) (NN:[322..335] protooncogene))
          (NP (NN:[336..341] N-myc)))))
    (VP (VBZ:[342..344] is)
      (NP-PRD
        (NP (DT:[345..348] the)
          (ADJP (RBS:[349..353] most) (JJ:[354..363] important))
          (JJ:[365..374] molecular) (NN:[375..389] characteristic))
        (VP (VBG:[390..400] predicting)
          (NP
            (NP (DT:[401..402] a) (JJ:[403..406] bad) (NN:[407..414] outcome))
            (PP (IN:[415..418] for)
              (NP (DT:[419..422] the) (NNS:[423..431] patients)))))))
    (.:[431..432] .)))

;sentence 6 Span:433..540
;Despite the  importance of the N-myc gene, little is known about the
;mechanisms regulating  its expression.
;[464..469]:gene-rna:"N-myc"
(SENT
  (S
    (PP (IN:[433..440] Despite)
      (NP
        (NP (DT:[441..444] the) (NN:[446..456] importance))
        (PP (IN:[457..459] of)
          (NP (DT:[460..463] the) (NN:[464..469] N-myc) (NN:[470..474] gene)))))
    (,:[474..475] ,)
    (NP-SBJ-1 (JJ:[476..482] little))
    (VP (VBZ:[483..485] is)
      (VP (VBN:[486..491] known)
        (NP-1 (-NONE-:[491..491] *))
        (PP (IN:[492..497] about)
          (NP
            (NP (DT:[498..501] the) (NNS:[502..512] mechanisms))
            (VP (VBG:[513..523] regulating)
              (NP (PRP$:[525..528] its) (NN:[529..539] expression)))))))
    (.:[539..540] .)))

;sentence 7 Span:541..657
;We found evidence that insulin-like growth factor II stimulates  the growth
;of neuroblastoma in a paracrine fashion.
;[564..593]:gene-protein:"insulin-like growth factor II"
;[620..633]:malignancy-type:"neuroblastoma"
(SENT
  (S
    (NP-SBJ (PRP:[541..543] We))
    (VP (VBD:[544..549] found)
      (NP
        (NP (NN:[550..558] evidence))
        (SBAR (IN:[559..563] that)
          (S
            (NP-SBJ
              (ADJP (NN:[564..571] insulin) (HYPH:[571..572] -)
                    (JJ:[572..576] like))
              (NML (NN:[577..583] growth) (NN:[584..590] factor))
              (CD:[591..593] II))
            (VP (VBZ:[594..604] stimulates)
              (NP
                (NP (DT:[606..609] the) (NN:[610..616] growth))
                (PP (IN:[617..619] of)
                  (NP (NN:[620..633] neuroblastoma))))
              (PP (IN:[634..636] in)
                (NP (DT:[637..638] a) (JJ:[639..648] paracrine)
                    (NN:[649..656] fashion))))))))
    (.:[656..657] .)))

;sentence 8 Span:658..776
;Two neuroblastoma cell lines  predominantly expressed IGF-II whereas two
;other cell lines expressed the  IGF-receptor.
;[662..675]:malignancy-type:"neuroblastoma"
;[712..718]:gene-protein:"IGF-II"
;[763..775]:gene-protein:"IGF-receptor"
(SENT
  (S
    (NP-SBJ (CD:[658..661] Two) (NN:[662..675] neuroblastoma)
            (NN:[676..680] cell) (NNS:[681..686] lines))
    (ADVP (RB:[688..701] predominantly))
    (VP (VBD:[702..711] expressed)
      (NP (NN:[712..718] IGF-II))
      (SBAR-ADV (IN:[719..726] whereas)
        (S
          (NP-SBJ (CD:[727..730] two) (JJ:[731..736] other) (NN:[737..741] cell)
                  (NNS:[742..747] lines))
          (VP (VBD:[748..757] expressed)
            (NP (DT:[758..761] the)
               (NN:[763..766] IGF) (HYPH:[766..767] -) (NN:[767..775] receptor))))))
    (.:[775..776] .)))

;sentence 9 Span:777..869
;In a receptor-positive cell line, N-myc expression was enhanced by 
;stimulation with IGF-II.
;[811..816]:gene-rna:"N-myc"
;[862..868]:gene-protein:"IGF-II"
(SENT
  (S
    (PP (IN:[777..779] In)
      (NP (DT:[780..781] a)
        (ADJP (NN:[782..790] receptor) (HYPH:[790..791] -)
              (JJ:[791..799] positive))
        (NN:[800..804] cell) (NN:[805..809] line)))
    (,:[809..810] ,)
    (NP-SBJ-1 (NN:[811..816] N-myc) (NN:[817..827] expression))
    (VP (VBD:[828..831] was)
      (VP (VBN:[832..840] enhanced)
        (NP-1 (-NONE-:[840..840] *))
        (PP-MNR (IN:[841..843] by)
          (NP
            (NP (NN:[845..856] stimulation))
            (PP (IN:[857..861] with)
              (NP (NN:[862..868] IGF-II)))))))
    (.:[868..869] .)))

;sentence 10 Span:870..1057
;As the growth-stimulating signals of the IGF receptor  are transmitted via
;Ras proteins, inactivation of Ras is one promising tool to  prevent the
;induction of N-myc expression by IGF-II.
;[911..923]:gene-protein:"IGF receptor"
;[945..948]:gene-protein:"Ras"
;[975..978]:gene-protein:"Ras"
;[1030..1035]:gene-rna:"N-myc"
;[1050..1056]:gene-protein:"IGF-II"
(SENT
  (S
    (SBAR-ADV (IN:[870..872] As)
      (S
        (NP-SBJ-2
          (NP (DT:[873..876] the)
            (ADJP (NN:[877..883] growth) (HYPH:[883..884] -)
                  (VBG:[884..895] stimulating))
            (NNS:[896..903] signals))
          (PP (IN:[904..906] of)
            (NP (DT:[907..910] the)
               (NN:[911..914] IGF) (NN:[915..923] receptor))))
        (VP (VBP:[925..928] are)
          (VP (VBN:[929..940] transmitted)
            (NP-2 (-NONE-:[940..940] *))
            (PP-MNR (IN:[941..944] via)
              (NP (NN:[945..948] Ras) (NNS:[949..957] proteins)))))))
    (,:[957..958] ,)
    (NP-SBJ
      (NP (NN:[959..971] inactivation))
      (PP (IN:[972..974] of)
        (NP (NN:[975..978] Ras))))
    (VP (VBZ:[979..981] is)
      (NP-PRD
        (NP (CD:[982..985] one) (JJ:[986..995] promising) (NN:[996..1000] tool))
        (SBAR
          (WHNP-1 (-NONE-:[1000..1000] 0))
          (S
            (NP-SBJ-1 (-NONE-:[1000..1000] *))
            (VP (TO:[1001..1003] to)
              (VP (VB:[1005..1012] prevent)
                (NP
                  (NP (DT:[1013..1016] the) (NN:[1017..1026] induction))
                  (PP (IN:[1027..1029] of)
                    (NP (NN:[1030..1035] N-myc) (NN:[1036..1046] expression)))
                  (PP (IN:[1047..1049] by)
                    (NP (NN:[1050..1056] IGF-II))))))))))
    (.:[1056..1057] .)))

;sentence 11 Span:1058..1229
;Treatment of neuroblastoma  cells with an inhibitor of the
;farnesyl-protein-transferase (FPTase) inactivated  H-ras protein completely
;and N-ras protein by more than 50 %.
;[1071..1091]:malignancy-type:"neuroblastoma  cells"
;[1117..1145]:gene-protein:"farnesyl-protein-transferase"
;[1147..1153]:gene-protein:"FPTase"
;[1168..1173]:gene-protein:"H-ras"
;[1197..1202]:gene-protein:"N-ras"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1058..1067] Treatment))
      (PP (IN:[1068..1070] of)
        (NP (NN:[1071..1084] neuroblastoma) (NNS:[1086..1091] cells)))
      (PP (IN:[1092..1096] with)
        (NP
          (NP (DT:[1097..1099] an) (NN:[1100..1109] inhibitor))
          (PP (IN:[1110..1112] of)
            (NP (DT:[1113..1116] the)
              (NML
                (NML (NN:[1117..1125] farnesyl) (HYPH:[1125..1126] -)
                     (NN:[1126..1133] protein) (HYPH:[1133..1134] -)
                     (NN:[1134..1145] transferase))
                (NML (-LRB-:[1146..1147] -LRB-) (NN:[1147..1153] FPTase)
                     (-RRB-:[1153..1154] -RRB-))))))))
    (VP
      (VP (VBD:[1155..1166] inactivated)
        (NP=1 (NN:[1168..1173] H-ras) (NN:[1174..1181] protein))
        (ADVP=2 (RB:[1182..1192] completely)))
      (CC:[1193..1196] and)
      (VP
        (NP=1 (NN:[1197..1202] N-ras) (NN:[1203..1210] protein))
        (PP=2 (IN:[1211..1213] by)
          (NP
            (QP (JJR:[1214..1218] more) (IN:[1219..1223] than)
                (CD:[1224..1226] 50))
            (NN:[1227..1228] %)))))
    (.:[1228..1229] .)))

;sentence 12 Span:1230..1341
;Cell growth of  neuroblastoma cells in serum containing medium was clearly
;diminished by  inhibition of FPTase.
;[1246..1265]:malignancy-type:"neuroblastoma cells"
;[1334..1340]:gene-protein:"FPTase"
(SENT
  (S
    (NP-SBJ-1
      (NP (NN:[1230..1234] Cell) (NN:[1235..1241] growth))
      (PP (IN:[1242..1244] of)
        (NP (NN:[1246..1259] neuroblastoma) (NNS:[1260..1265] cells)))
      (PP (IN:[1266..1268] in)
        (NP
          (ADJP (NN:[1269..1274] serum) (VBG:[1275..1285] containing))
          (NN:[1286..1292] medium))))
    (VP (VBD:[1293..1296] was)
      (ADVP (RB:[1297..1304] clearly))
      (VP (VBN:[1305..1315] diminished)
        (NP-1 (-NONE-:[1315..1315] *))
        (PP (IN:[1316..1318] by)
          (NP-LGS
            (NP (NN:[1320..1330] inhibition))
            (PP (IN:[1331..1333] of)
              (NP (NN:[1334..1340] FPTase)))))))
    (.:[1340..1341] .)))

;sentence 13 Span:1342..1452
;The growth-promoting effect of IGF-II was reduced to  exactly half the amount
;observed in non-inhibited cells.
;[1373..1379]:gene-protein:"IGF-II"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[1342..1345] The)
        (ADJP (NN:[1346..1352] growth) (HYPH:[1352..1353] -)
              (VBG:[1353..1362] promoting))
        (NN:[1363..1369] effect))
      (PP (IN:[1370..1372] of)
        (NP (NN:[1373..1379] IGF-II))))
    (VP (VBD:[1380..1383] was)
      (VP (VBN:[1384..1391] reduced)
        (NP-1 (-NONE-:[1391..1391] *))
        (PP (TO:[1392..1394] to)
          (NP
            (NP
              (QP (RB:[1396..1403] exactly) (RB:[1404..1408] half))
              (DT:[1409..1412] the) (NN:[1413..1419] amount))
            (VP (VBN:[1420..1428] observed)
              (NP (-NONE-:[1428..1428] *))
              (PP (IN:[1429..1431] in)
                (NP
                  (ADJP (AFX:[1432..1435] non) (HYPH:[1435..1436] -)
                        (VBN:[1436..1445] inhibited))
                  (NNS:[1446..1451] cells))))))))
    (.:[1451..1452] .)))

;section 14 Span:1456..1501
;PMID: 11807663 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1456..1460] PMID) (::[1460..1461] :) (CD:[1462..1470] 11807663)
        (NN:[1471..1472] -LSB-) (NNP:[1472..1478] PubMed) (::[1479..1480] -)
        (NN:[1481..1488] indexed) (IN:[1489..1492] for)
        (NNP:[1493..1501] MEDLINE-RSB-)))
